Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

Delayed Quote. Delayed  - 06/30 05:35:01 pm
1604.5 GBp   +2.89%
04:15p GLAXOSMITHKLINE : GSK announces start of phase I oncology study with..
01:59pDJGLAXOSMITHKLINE : Starts Phase-1 for Antibody Clinical Trial
01:25p GLAXOSMITHKLINE : Starts Clinical Trial On GSK3359609 Cancer Treatme..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201320142015201620172018
Sales26 50523 00623 92325 71426 50127 698
Operating income (EBITDA)8 8838 0457 0288 5258 8249 242
Operating profit (EBIT)8 0156 5945 7296 8047 1567 698
Pre-Tax Profit (EBT)6 6472 96810 5264 4785 1476 016
Net income5 6282 7568 4222 7973 4314 242
P/E ratio0,150,240,0831,123,819,8
EPS (PNC )11156,717250,265,478,7
Dividend per Share (PNC )78,080,080,081,780,081,3
Yield484%581%583%5,24%5,13%5,21%
Reference price (PNC )16.113.813.71559.51559.51559.5
Announcement Date02/05/2014
12:00pm
02/04/2015
03:18pm
02/03/2016
12:00pm
---
Finances - Leverage
Actuals in M GBP Estimates in M GBP
Fiscal Period December 201320142015201620172018
Debt12 64514 37710 72712 79112 89512 430
Finance------
Operating income (EBITDA)8 8838 0457 0288 5258 8249 242
Leverage
(Debt/EBITDA)
1,42x1,79x1,53x1,50x1,46x1,35x
Capital Expenditure1 1881 1881 3801 6981 5081 457
Book Value Per Share (BVPS)146 PNC87,6 PNC106 PNC73,5 PNC75,6 PNC83,4 PNC
Cash Flow per Share149 PNC108 PNC53,2 PNC108 PNC127 PNC134 PNC
Announcement Date02/05/2014
12:00pm
02/04/2015
03:18pm
02/03/2016
12:00pm
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 75 976 M GBP -
Entreprise Value (EV) 88 767 M GBP 88 871 M GBP
Valuation 2016e 2017e
P/E ratio (Price / EPS) 31,1x 23,8x
Capitalization / Revenue 2,95x 2,87x
EV / Revenue 3,45x 3,35x
EV / EBITDA 10,4x 10,1x
Yield (DPS / Price) 5,24% 5,13%
Price to book (Price / BVPS) 21,2x 20,6x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 26,5% 27,0%
operating Leverage (Delta EBIT / Delta Sales) 2,51x 1,69x
Net Margin (Net Profit / Revenue) 10,9% 12,9%
ROA (Net Profit / Asset) 7,20% 8,44%
ROE (Net Profit / Equities) 84,8% 116%
Rate of Dividend 163% 122%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   6,60% 5,69%
Cash Flow / Sales 20,4% 23,4%
Capital Intensity (Assets / Sales) 1,51x 1,53x
Financial Leverage (Net Debt / EBITDA) 1,50x 1,46x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend